Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scanning Guardant Health’s 10-K can feel like wading through both biotech jargon and accounting footnotes. Key details on liquid biopsy test volumes, FDA submissions, and R&D burn rates are scattered across hundreds of pages, while Form 4 insider sales from the founders often appear without context. If you have ever searched “Guardant Health SEC filings explained simply” or asked, “Where can I find the Guardant Health quarterly earnings report 10-Q filing?”, you know the challenge.
Stock Titan solves it. Our AI-powered summaries translate dense cancer-genomics language into clear insights, flagging segment revenue shifts and clinical milestone disclosures in seconds. Need real-time alerts? The moment a “Guardant Health Form 4 insider transactions real-time” filing hits EDGAR, we surface it alongside easy-to-read charts of executive stock transactions. Drill into any document:
- Guardant Health annual report 10-K simplified – spot test-volume growth and cash runway.
- Guardant Health quarterly earnings report 10-Q filing – track sequential margin changes.
- Guardant Health 8-K material events explained – catch trial results or reimbursement wins.
- Guardant Health proxy statement executive compensation – review R&D-weighted incentive plans.
Whether you’re modeling future oncology revenues or monitoring “Guardant Health earnings report filing analysis” for competitive intelligence, Stock Titan provides AI guidance that saves hours. Join institutional investors who are already “understanding Guardant Health SEC documents with AI” to make informed decisions faster.
Guardant Health, Inc. (GH) – SEC Form 4 filing dated 07/07/2025
Director Meghan V. Joyce reported the acquisition of 66 common shares on 07/04/2025 through the settlement of previously granted Restricted Stock Units (RSUs). The RSUs carried a $0 conversion price, so no cash changed hands. Following the transaction, Joyce’s direct beneficial ownership increases to 11,216 common shares.
The underlying RSU award vested 25 % on 08/04/2022, with the remaining 75 % vesting in equal monthly installments over three years (through 08/04/2025). No derivative securities were disposed of, and the transaction was coded “M” (acquisition from the company without open-market purchase).
The filing is routine, involves a small share count relative to Guardant Health’s outstanding shares, and contains no financial performance information or strategic disclosures.
Guardant Health, Inc. (GH) – Form 4 filing (07/02/2025)
Chief Information Officer Kumud Kalia reported routine equity transactions tied to the vesting of previously granted restricted stock units (RSUs) on July 1 2025:
- 2,691 common shares were issued upon the automatic conversion of RSUs (Transaction Code M) at a zero exercise price.
- 1,365 shares were simultaneously surrendered to the company to cover statutory tax-withholding obligations (Transaction Code F) at a market price of $50.71.
- After the net share settlement, Kalia’s direct ownership increased by 1,326 shares to a total of 20,500 common shares.
The derivative table shows that the executive still holds 8,035 unvested RSUs from a November 7 2022 grant and 5,419 unvested RSUs from a December 13 2023 grant, each vesting quarterly over their remaining terms. No open-market sales or purchases were reported beyond the withheld shares, indicating that the insider retained all newly vested stock net of taxes.
This filing reflects standard equity-compensation activity; it does not disclose any new option grants, cash transactions, or information that would materially alter Guardant Health’s financial outlook. The scale of the net acquisition is immaterial relative to the company’s total shares outstanding, but it modestly increases insider alignment.
Guardant Health, Inc. (GH) – Form 4 insider transaction, filed 2 Jul 2025
Chief Commercial Officer Chris Freeman reported automatic vesting of two restricted-stock-unit (RSU) tranches on 1 Jul 2025:
- 1,929 shares from a November 2022 RSU grant.
- 1,667 shares from a December 2023 RSU grant.
Both conversions were coded “M” (exempt), reflecting zero exercise price. To cover associated tax obligations, the company withheld 1,532 shares (Code “F”) at a market price of $50.71.
After the transactions, Freeman’s direct ownership rose by a net ≈2,064 shares to 48,821 shares. No open-market purchases or discretionary sales occurred; all movements relate to routine equity compensation vesting and withholding.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
